Pharmaceutical Life Cycle Management: Updates on Navigating the IP, FDA and Antitrust Terrain

Events / Wednesday, April 5, 2017

There’s been a sea change in the political climate. The regulatory forecast is still uncertain, and pharmaceutical evolution continues to develop.

Efforts to extend the life cycle of pharmaceutical products frequently involve innovations and improvements in product design, formulation, route of administration and treatment indications. In addition, negotiation of agreements with competitors, including generic and biosimilar manufacturers, is frequently employed as part of a life cycle management strategy. However, recent changes in patent, regulatory and antitrust laws have introduced considerable complexity and risk into these strategies.

Be prepared for what the next year may bring by attending this important webinar, which brings together our experienced professionals to talk about these issues and approaches for successful pharmaceutical life cycle management.

  • Carl W. Hittinger, Partner, Philadelphia
  • Lee H. Rosebush, Partner, Washington, D.C.
  • Lance L. Shea, Partner, Washington, D.C.
  • S. Maurice Valla, Partner, Philadelphia


In The Blogs

Previous Next
Antitrust Advocate
Join Us for a Teleconference on New ABA Publication, “Antitrust Class Actions Handbook”
February 20, 2018
The ABA recently released a new publication that should be of interest to antitrust practitioners, the Antitrust Class Actions Handbook, Second Edition. The Handbook comprehensively addresses issues that arise before, during and after the...
Antitrust Advocate
No Health Care Merger Too Small for the FTC to Take an Antitrust Look
February 12, 2018
In our November and December 2016 articles, we discussed the Federal Trade Commission’s proclivity to challenge health care mergers, even when the purported anticompetitive effects of the relatively economically limited merger would be...
Health Law Update
Capitol Hill Healthcare Update
February 12, 2018
TRUMP TO RELEASE FISCAL 2019 BUDGET THIS MORNING The White House this morning is releasing President Trump’s fiscal 2019 budget blueprint, which will include funding requests for HHS, FDA, CMS and dozens of other healthcare-related federal...
IP Intelligence: Insight on Intellectual Property
Core Wireless: Moving Beyond Eligibility as the Exception to the Exception?
By Brendan E. Clark
February 8, 2018
January was an exciting month for patent professionals still attempting to make sense of the fallout from the Supreme Court’s 2014 Alice Corp. v. CLS Bank International decision. Hot on the heels of its Jan. 10 decision in Finjan, Inc. v...
Antitrust Advocate
Has the Third Circuit Just Scrambled ‘Umbrella Damages’?
February 6, 2018
A recent decision by the Third Circuit permits plaintiffs to pursue antitrust damages for egg products supplied by non-conspiring parties. This decision could represent a crack in the “umbrella damages” rule that precludes plaintiffs from...